I think it’s the low cash levels to fund the business.
Strategic review may be about how to survive until it’s cash flow positive.
Really just needs to book revenue. Desperately. And I think the lack of news on this front and the reasons behind customer inaction is scaring people.
- Forums
- ASX - By Stock
- PET
- UK Market
UK Market, page-26
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PET (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online